Latest news with #EuronextBrussels
Yahoo
9 hours ago
- Business
- Yahoo
Press release: Transparency Notification from Shareholders
Transparency Notification from Shareholders Ghent, Belgium – 6 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entity listed below, notifying the number of voting rights attached to the shares mentioned next to its name in the table below. Reason for notification Aggregate number of shares and voting rights held % of total outstanding shares (1) GRAC société simple (2) Acquisition or transfer of voting securities or voting rights 2,796,929 5.12% _____________Notes: (1) The total number of outstanding shares of the Company mentioned in the relevant transparency notification amounts to 54,671,074, each share giving right to one (1) vote (being 54,671,074 voting rights in total).(2) The notification, dated 6 June 2025 and received by the Company on 3 June 2025, was made by GRAC société simple ("GRAC"), acting as a person that notifies alone. The notification states that on 14 May 2025, the total shareholding of GRAC (holding 2,796,929 shares and voting rights, which corresponds to 5.12% of the outstanding voting rights of the Company at that time) had crossed the threshold of 5% of the outstanding voting rights of the Company. The notification further specifies that GRAC is not controlled by another entity or holding. The notification also states that the aforementioned threshold was crossed following the conversion of a convertible loan. This announcement is made in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions. To access a copy of the aforementioned transparency notification, reference is made to Sequana Medical's website ( Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company. For more information, please contact: Sequana Medical Investor relationsE: IR@ T: +32 9 292 8065 About Sequana Medical Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic resistant" patient population. alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, and are intended to deliver major clinical and quality of life benefits for patients, while reducing costs for healthcare systems. The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. Sequana Medical intends to start US commercialisation in Q3 2025 through a small specialty sales force that it will establish to target the 90 US liver transplant centers that perform 95% of liver transplants. Results of the Company's RED DESERT and SAHARA proof-of-concept studies in heart failure published in European Journal of Heart Failure in April 2024 support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements1. Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: and headquartered in Ghent, Belgium. For further information, please visit For important safety information regarding the alfapump® system, see The alfapump® System is currently not approved in Canada. DSR® therapy is still in development and is currently not approved in any country. The safety and effectiveness of DSR® therapy has not been established. Note: alfapump® and DSR® are registered trademarks. Forward-looking statements This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release. 1 Data reported in press release of March 25, 2024; mean increase of 326% in six-hour urinary sodium excretion at 3 months follow up vs baseline, and 95% reduction of loop diuretics over same period. Attachments Sequana Medical - GRAC Transparency Notification PR (ENG) - (6 June 2025) Sequana Medical - GRAC Transparency Notification PR (NL) - (6 June 2025)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Business
- Yahoo
Bekaert - Update on the Share Buyback Program and the Liquidity Agreement
Update on the Share Buyback Program and the Liquidity Agreement Period from 29 May 2025 to 4 June 2025 Share Buyback ProgramOn 28 February 2025, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 29 May 2025 to 4 June 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 61 620 shares. The table below provides an overview of the transactions under the Program during the period from 29 May 2025 to 4 June 2025:Repurchase of shares Date Market Number of Shares Average Price paid (€) Highest Price paid (€) Lowest Price paid (€) Total Amount (€) 29 May 2025 Euronext Brussels 8 000 35.68 35.85 35.45 285 440MTF CBOE 4 000 35.67 35.85 35.50 142 680MTF Turquoise —MTF Aquis — 30 May 2025 Euronext Brussels 8 000 35.68 35.90 35.35 285 440MTF CBOE 4 000 35.67 35.90 35.35 142 680MTF Turquoise —MTF Aquis — 2 June 2025 Euronext Brussels 7 323 35.61 35.80 35.30 260 772MTF CBOE 3 893 35.60 35.75 35.30 138 591MTF Turquoise —MTF Aquis — 3 June 2025 Euronext Brussels 8 500 35.41 35.55 35.30 300 985MTF CBOE 4 404 35.45 35.55 35.30 156 122MTF Turquoise —MTF Aquis — 4 June 2025 Euronext Brussels 8 500 35.77 36.20 35.25 304 045MTF CBOE 5 000 35.73 36.20 35.40 178 650MTF Turquoise MTF AquisTotal61 620 35.63 36.20 35.25 2 195 405 Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 25 June 2024, Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 2 500 shares during the period from 29 May 2025 to 4 June 2025 on Euronext Brussels. During the same period, Kepler Cheuvreux on behalf of Bekaert has sold 2 300 shares on Euronext Brussels. The tables below provide an overview of the transactions under the liquidity agreement during the period from 29 May 2025 to 4 June 2025:Purchase of shares Date Number of Shares Average Price (€) Highest Price (€) Lowest Price (€) Total Amount (€) 29 May 2025 200 35.50 35.50 35.50 7 100 30 May 2025 200 35.30 35.30 35.30 7 060 2 June 2025 800 35.40 35.50 35.25 28 320 3 June 2025 500 35.36 35.40 35.25 17 680 4 June 2025 800 35.35 35.50 35.30 28 280 Total 2 50088 440 Sale of shares Date Number of Shares Average Price (€) Highest Price (€) Lowest Price (€) Total Amount (€) 29 May 2025 700 35.66 35.80 35.60 24 962 30 May 2025 567 35.82 36.00 35.70 20 310 2 June 2025 0 0.00 0.00 0.00 0 3 June 2025 0 0.00 0.00 0.00 0 4 June 2025 1 033 35.90 36.20 35.75 37 085 Total 2 30082 357 The balance held by Bekaert under the liquidity agreement at the end of the period is 34 867 shares. On 4 June 2025 after closing of the market, Bekaert holds 1 820 450 own shares, or 3.45% of the total number of the outstanding shares. This information is also made available on the investor relations pages of our website. Attachment p250606E - Bekaert - Update on the Share Buyback Program and the Liquidity AgreementSign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Campine expects a substantial surge in profits in 2025 due to the rise in demand for its antimony products.
Regulated information – Inside information - May 28th 2025 – 08:00 Campine NV, metals recycling and specialty chemicals company from Beerse, Belgium and listed on Euronext Brussels expects substantially higher profits for 2025 as a result of the increased demand for its antimony products. Due to export restrictions in China since the fall of 2024, Campine and other suppliers benefit from a considerable surge in demand. 'In the last months we booked orders from new customers around the globe' CEO De Vos explains. 'Our global sales volumes of antimony trioxide have increased on average with 35% and given the lowered demand in Europe the overseas sales have in fact more than doubled'. Antimony metal prices have now reached a record level of 60.000 USD/ton. 'At this price level we also expect much higher sales revenue and profits'. Campine is forecasting a sales revenue of about 380 M€ and an EBITDA of at least 50 M€ only for the first semester of 2025, in comparison with 169 M€ sales and an EBITDA of 19,7 M€ for the first semester of last year 2024. For the full year it is too early to make predictions as markets are extremely volatile at this moment. Demand is also typically lower during the summer months. Moreover, antimony prices have stabilised in recent weeks, so the positive impact of the increased business volumes, prices and value augmentations of Campine's antimony stocks could be reduced or absent in the second year half. For further information you can contact Karin Leysen (tel. no +32 14 60 15 49)(email: Attachment 250528 Campine profits engError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Nyrstar NV releases notice for the 2024 annual general shareholders' meeting to be held on 24 June 2025
Regulated Information Nyrstar NV releases notice for the 2024 annual general shareholders' meeting to be held on 24 June 2025 23 May 2025 at 07.00 CEST Nyrstar NV (the 'Company') today issued the notice for the 2024 annual general shareholders' meeting to be held on 24 June 2025 at 11:00 a.m. CEST. The annual general meeting will be held physically with no virtual option available. The practical modalities of the meeting are set out in the notice to the meeting which has been published on the Company's website ( The full notice, including agenda, proposed resolutions and explanatory note can be found on the aforementioned Nyrstar NV website. About Nyrstar NV The Company is incorporated in Belgium and is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: For further information contact: Company Secretary Whyte Corporate Affairs - +32 2738 0620 nyrstar@ Attachment Nyrstar NV AGM 23052025 ENGLISH
Yahoo
23-05-2025
- Business
- Yahoo
Nyrstar NV releases notice for the 2024 annual general shareholders' meeting to be held on 24 June 2025
Regulated Information Nyrstar NV releases notice for the 2024 annual general shareholders' meeting to be held on 24 June 2025 23 May 2025 at 07.00 CEST Nyrstar NV (the 'Company') today issued the notice for the 2024 annual general shareholders' meeting to be held on 24 June 2025 at 11:00 a.m. CEST. The annual general meeting will be held physically with no virtual option available. The practical modalities of the meeting are set out in the notice to the meeting which has been published on the Company's website ( The full notice, including agenda, proposed resolutions and explanatory note can be found on the aforementioned Nyrstar NV website. About Nyrstar NV The Company is incorporated in Belgium and is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: For further information contact: Company Secretary Whyte Corporate Affairs - +32 2738 0620 nyrstar@ Attachment Nyrstar NV AGM 23052025 ENGLISHSign in to access your portfolio
